sur Temedica GmbH
Temedica Expands Advisory Board with Ex-Gematik CEO Markus Leyck Dieken
Munich-based health insights company, Temedica, has announced the addition of Dr. med. Markus Leyck Dieken to its Advisory Board. Leyck Dieken, the former CEO of Gematik, brings extensive experience in healthcare digital transformation. He will focus on strategic-regulatory issues at Temedica, leveraging his expertise in internal and emergency medicine, biotechnological product development and healthcare policy.
During his career, Leyck Dieken has held prominent roles, including leading the development of diabetes therapies at Novo Nordisk and managing the EU vaccine business at Novartis. He also contributed to combating antibiotic resistance at Shionogi Europe. His tenure as CEO of Gematik was marked significant advancements in Germany’s healthcare system through digital innovations.
Gloria Seibert, CEO of Temedica, emphasized that Leyck Dieken’s addition is a strategic asset, enhancing the company's capabilities in real-world evidence and personalized medicine. Leyck Dieken himself highlighted the potential of digital tools to revolutionize patient care through real-world evidence.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Temedica GmbH